# US 2017/0281652 A1 · Therapeutic Compositions and Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281652 A1
- Document ID: US20170281652A1
- Status: Published application
- Kind: A1
- Application number: 15/628,179
- Filed: 2017-06-20
- Published: 2017-10-05
- Earliest claimed: 2012-07-30
- Assignees: Pop Test Oncology LLC
- Applicants: Pop Test Oncology LLC
- Inventors: Randice Lisa Altschul; Neil David Theise; Myron Rapkin; Rebecca O'Brien
- Web page: https://patentgrep.com/patent/US20170281652A1

## CPC

- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/36: Opioid-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy.

## Claims

### Claim 1

A method for treating and/or preventing addiction to, and physiological dependence upon, addictive substances wherein said method comprises:
selecting a patient in need of treating and/or preventing addiction to, and physiological dependence upon, addictive substances;
administering to the patient in need of treating and/or preventing addiction to, and physiological dependence upon, addictive substances at least ORG 34517 in a therapeutically effective amount, thereby treating and/or preventing addiction to, and physiological dependence upon, addictive substances.

### Claim 2 (depends on 1)

The method of claim 1, wherein the addictive substance is selected from the group consisting of Opiates, opiate analogues, heroine, oxycodone, hydrocodone, hydromorphone, methadone, dextromethorphan, benzodiazepines, MDMA, GHB, barbiturates, khat, kratom, PCP, LSD, ketamine, peyote, mescaline, psilocybin, rohypnol, Salvia divinorum, antidepressants, anti-anxiety medications, sleep aids, allergy medications, and combinations thereof.

### Claim 3 (depends on 1)

The method, according to claim 1, wherein the at least ORG 34517 is in a pharmaceutical preparation.

### Claim 4

A method of treating and/or preventing addiction to, and physiological dependence upon, addictive substances in a patient in need thereof, comprising:
selecting a patient in need of treating and/or preventing addiction to, and physiological dependence upon, addictive substances;
administering a composition comprising:
i) ORG 34517, or pharmaceutically acceptable salts thereof;
ii) at least one additional therapeutic agent(s) selected from the group consisting of anxiolytics, antidepressants, neuroleptics, or other psychotropic medications and combinations thereof; and
iii) at least one pharmaceutically acceptable carrier, wherein the ORG 34517 and at least one additional therapeutic agents are each present in an amount which, in combination, is a therapeutically effective amount for treating or preventing the condition.

### Claim 5 (depends on 4)

The method of claim 4 wherein the addictive substance is selected from the group consisting of opiates, opiate analogues, heroine, oxycodone, hydrocodone, hydromorphone, methadone, dextromethorphan, benzodiazepines, MDMA, GHB, barbiturates, khat, kratom, PCP, LSD, ketamine, peyote, mescaline, psilocybin, rohypnol, Salvia divinorum, antidepressants, anti-anxiety medications, sleep aids, allergy medications, and combinations thereof.

### Claim 6 (depends on 4)

The method of claim 4 wherein the additional therapeutic agent is selected from the group consisting of at least one anti-anxiety drug, at least one anti-depressant drug, and at least one neuroleptic medication and combinations thereof, wherein the at least one anti-anxiety drug is selected from the group consisting of alprazolam, bromazepam, diazepam, lorazepam, clonazepam, temazepam, oxazepam, flunitrazepam, triazolam, chlordiazepoxide, flurazepam, estazolam, nitrazepam, and pharmaceutically acceptable salts, isomers, and mixtures thereof; and/or at least one anti-depressant drug selected from the group consisting of citalopram, escitalopram oxalate, fluoxetine, fluvoxamine, paroxetine, sertraline, dapoxetine; venlafaxine and duloxetine; harmaline, iproniazid, isocarboxazid, nialamide, pargyline, phenelzine, selegiline, toloxatone, tranylcypromine, brofaromine, moclobemide; amitriptyline, amoxapine, butriptyline, clomipramine, desipramine, dibenzepin, dothiepin, doxepin, imipramine, iprindole, lofepramine, melitracen, nortriptyline, opipramol, protriptyline, trimipramine; maprotiline, mianserin, nefazodone, trazodone, and pharmaceutically acceptable salts, isomers, and combinations thereof and/or at least one neuroleptic drug selected from the group consisting of Haloperidol, Droperidol, Benperidol, Triperidol, Melperone, Lenperone, azaperone, Domperidone, risperidone, Chlorpromazine, Fluphenazine, Perphenazine, Prochlorperazine, Thioridazine, Trifluoperazine, Mesoridazine, Periciazine, Promazine, Triflupromazine, Levomepromazine, Promethazine, Pimozide, Cyamemazine, Chlorprothixene, Clopenthixol, Flupenthixol, Thiothixene, Zuclopenthixol, Clozapine, Olanzapine, Risperidone, Quetiapine, Ziprasidone, Amisulpride, Asenapine, Paliperidone, Iloperidone, Zotepine, Sertindole, Lurasidone, Aripiprazole, and pharmaceutically acceptable salts, isomers, and combinations thereof.

### Claim 7

A method of treating and/or preventing addiction to, and physiological dependence upon, addictive substances in a patient, comprising the steps of:
a) obtaining a test sample from the patient using a test sample collection unit;
b) combining said test sample with a buffering system to form a mixture in a reaction unit;
c) measuring a parameter of the mixture to determine a blank measurement;
d) combining said test sample and buffer mixture with a labeled ligand which binds cortisol in the reaction unit to produce an assay solution; or combining said test sample and buffer mixture and delivering it to a carrier containing a labeled ligand which binds cortisol in the reaction unit to produce an assay immobilized complex;
e) measuring a parameter of said assay solution or complex;
f) comparing the measurement of the assay solution relative to the blank measurement;
g) determining the patient's circulating cortisol levels based on the change of the measurement;
h) comparing the measured cortisol levels to a predetermined reference range cortisol levels, wherein when the level of cortisol is elevated relative to the predetermined reference range, then the patient has elevated cortisol, and thus is suitable for GCR (glucocorticoid receptor) antagonist therapy; and
i) when the patient is suitable for GCR antagonist therapy, administering at least ORG 34517, thereby treating and/or preventing addiction to, and physiological dependence upon, addictive substances in the patient.

### Claim 8 (depends on 7)

The method of claim 7, wherein the patient's test sample is selected from the group consisting of saliva, blood, plasma, serum, urine, other bodily fluids, and combinations thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the sample is obtained from the patient one time, selected from the group consisting of morning, noon, and evening.

### Claim 10 (depends on 7)

The method of claim 7, wherein the sample is obtained from the patient over more than one time, and the predetermined time is selected to determine the nature of the cortisol circadian rhythm (including its possible disruption or elimination) from the group consisting of morning, noon, and evening.

### Claim 11 (depends on 7)

The method of claim 7, wherein the sample is obtained from the patient over consecutive days.

### Claim 12 (depends on 7)

The method of claim 7, wherein the method is to determine the circadian cycle of the cortisol levels in the patient, and the predetermined time is selected from the group consisting of hourly, every 4 hours, every 6 hours, every 8 hours, and every 12 hours.

### Claim 13 (depends on 7)

The method of claim 7, wherein the predetermined reference range is a medically standard reference range.

### Claim 14 (depends on 7)

The method of claim 7, wherein the predetermined reference range is the patient's previously measured level.

### Claim 15 (depends on 7)

The method of claim 7, wherein the ligand is detectably labeled with a moiety selected from the group consisting of a radioisotope, a fluorophore, a quencher of fluorescence, an enzyme, an affinity tag, and an epitope tag.

### Claim 16 (depends on 7)

The method of claim 7, wherein said measuring of said parameter of said mixture and said assay solution is performed using a method selected from spectroscopic, photochemical, radiochemical, biochemical, enzymatic, immunochemical, chemical label displacement, surface plasmon resonance, fluorescence resonance energy transfer, fluorescence quenching, lateral flow, and fluorescence polarization means.

### Claim 17 (depends on 7)

The method of claim 7, wherein the addictive substance is selected from the group consisting of opiates, opiate analogues, heroine, oxycodone, hydrocodone, hydromorphone, methadone, dextromethorphan, benzodiazepines, MDMA, GHB, barbiturates, khat, kratom, PCP, LSD, ketamine, peyote, mescaline, psilocybin, rohypnol, Salvia divinorum, antidepressants, anti-anxiety medications, sleep aids, allergy medications, and combinations thereof.
